Suppr超能文献

立体定向体部放疗采用实时肿瘤追踪的门控放疗治疗 I 期非小细胞肺癌。

Stereotactic body radiotherapy using gated radiotherapy with real-time tumor-tracking for stage I non-small cell lung cancer.

机构信息

Department of Radiation Medicine, Hokkaido University Graduate School of Medicine, North 15 West 7, Kita-ku, Sapporo 060-8638, Japan.

出版信息

Radiat Oncol. 2013 Mar 21;8:69. doi: 10.1186/1748-717X-8-69.

Abstract

BACKGROUND

To clarify the clinical outcomes of two dose schedule of stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) using a real-time tumor-tracking radiation therapy (RTRT) system in single institution.

METHODS

Using a superposition algorithm, we administered 48 Gy in 4 fractions at the isocenter in 2005-2006 and 40 Gy in 4 fractions to the 95% volume of PTV in 2007-2010 with a treatment period of 4 to 7 days. Target volume margins were fixed irrespective of the tumor amplitude.

RESULTS

In total, 109 patients (79 T1N0M0 and 30 T2N0M0). With a median follow-up period of 25 months (range, 4 to 72 months), the 5-year local control rate (LC) was 78% and the 5-year overall survival rate (OS) was 64%. Grade 2, 3, 4, and 5 radiation pneumonitis (RP) was experienced by 15 (13.8%), 3 (2.8%), 0, and 0 patients, respectively. The mean lung dose (MLD) and the volume of lung receiving 20 Gy (V20) were significantly higher in patients with RP Grade 2/3 than in those with RP Grade 0/1 (MLD p = 0.002, V20 p = 0.003). There was no correlation between larger maximum amplitude of marker movement and larger PTV (r = 0.137), MLD (r = 0.046), or V20 (r = 0.158).

CONCLUSIONS

SBRT using the RTRT system achieved LC and OS comparable to other SBRT studies with very low incidence of RP, which was consistent with the small MLD and V20 irrespective of tumor amplitude. For stage I NSCLC, SBRT using RTRT was suggested to be reliable and effective, especially for patients with large amplitude of tumor movement.

摘要

背景

为了明确在单机构中使用实时肿瘤跟踪放射治疗(RTRT)系统对 I 期非小细胞肺癌(NSCLC)进行两种剂量分割立体定向体放射治疗(SBRT)的临床结果。

方法

在 2005-2006 年,我们使用叠加算法在等中心点给予 48 Gy/4 次分割,在 2007-2010 年给予 40 Gy/4 次分割,使 PTV 的 95%体积达到 40 Gy。目标体积边界固定,与肿瘤幅度无关。

结果

共纳入 109 例患者(79 例 T1N0M0 和 30 例 T2N0M0)。中位随访时间为 25 个月(4-72 个月),5 年局部控制率(LC)为 78%,5 年总生存率(OS)为 64%。2 级、3 级、4 级和 5 级放射性肺炎(RP)的发生率分别为 15(13.8%)、3(2.8%)、0 和 0 例。RP 2/3 级患者的平均肺剂量(MLD)和 20 Gy 体积(V20)明显高于 RP 0/1 级患者(MLD p=0.002,V20 p=0.003)。标记物运动最大幅度与 PTV 较大(r=0.137)、MLD 较大(r=0.046)或 V20 较大(r=0.158)之间无相关性。

结论

使用 RTRT 系统的 SBRT 实现了与其他 SBRT 研究相当的 LC 和 OS,放射性肺炎发生率非常低,这与 MLD 和 V20 较小有关,而与肿瘤幅度无关。对于 I 期 NSCLC,使用 RTRT 的 SBRT 是可靠和有效的,特别是对于肿瘤运动幅度较大的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fc1/3614446/6387505fbac1/1748-717X-8-69-1.jpg

相似文献

3
A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy.
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):457-62. doi: 10.1016/j.ijrobp.2010.08.056. Epub 2010 Oct 29.
5
Potential reduction of lung dose via VMAT with jaw tracking in the treatment of single-isocenter/two-lesion lung SBRT.
J Appl Clin Med Phys. 2019 May;20(5):55-63. doi: 10.1002/acm2.12580. Epub 2019 Apr 5.
6
Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer.
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e545-9. doi: 10.1016/j.ijrobp.2012.01.018. Epub 2012 Mar 19.
7
Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer.
Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1015-22. doi: 10.1016/j.ijrobp.2010.03.012. Epub 2010 Jul 7.
8
Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung.
Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):190-5. doi: 10.1016/j.ijrobp.2012.03.041. Epub 2012 Aug 25.
10
Evaluation of plan quality and treatment efficiency for single-isocenter/two-lesion lung stereotactic body radiation therapy.
J Appl Clin Med Phys. 2019 Jan;20(1):118-127. doi: 10.1002/acm2.12500. Epub 2018 Dec 8.

引用本文的文献

2
Clinical application of real-time tumor-tracking for stereotactic volumetric modulated arc therapy for liver tumors.
Phys Imaging Radiat Oncol. 2024 Aug 5;31:100623. doi: 10.1016/j.phro.2024.100623. eCollection 2024 Jul.
4
Histology-driven hypofractionated radiation therapy schemes for early-stage lung adenocarcinoma and squamous cell carcinoma.
Radiother Oncol. 2024 Jun;195:110257. doi: 10.1016/j.radonc.2024.110257. Epub 2024 Mar 26.
6
Biomedical advances and future prospects of high-precision three-dimensional radiotherapy and four-dimensional radiotherapy.
Proc Jpn Acad Ser B Phys Biol Sci. 2023 Nov 10;99(9):389-426. doi: 10.2183/pjab.99.024. Epub 2023 Oct 12.
7
Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy.
J Transl Med. 2023 Jun 7;21(1):368. doi: 10.1186/s12967-023-04212-5.
8
Patient-specific respiratory motion management using lung tumors vs fiducial markers for real-time tumor-tracking stereotactic body radiotherapy.
Phys Imaging Radiat Oncol. 2022 Dec 24;25:100405. doi: 10.1016/j.phro.2022.12.002. eCollection 2023 Jan.

本文引用的文献

1
Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis.
Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):444-50. doi: 10.1016/j.ijrobp.2012.04.043. Epub 2012 Jun 9.
2
Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer: a multicenter study.
Radiother Oncol. 2012 Feb;102(2):246-50. doi: 10.1016/j.radonc.2011.10.016. Epub 2011 Nov 17.
3
Real-time 4-D radiotherapy for lung cancer.
Cancer Sci. 2012 Jan;103(1):1-6. doi: 10.1111/j.1349-7006.2011.02114.x. Epub 2011 Nov 14.
4
Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients.
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):967-73. doi: 10.1016/j.ijrobp.2010.12.039. Epub 2011 Mar 4.
5
Commissioning and quality assurance for a respiratory training system based on audiovisual biofeedback.
J Appl Clin Med Phys. 2010 Jul 12;11(4):3262. doi: 10.1120/jacmp.v11i4.3262.
6
A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy.
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):457-62. doi: 10.1016/j.ijrobp.2010.08.056. Epub 2010 Oct 29.
7
Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1352-8. doi: 10.1016/j.ijrobp.2009.07.1751. Epub 2010 Jul 16.
9
Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer.
Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1104-11. doi: 10.1016/j.ijrobp.2009.12.022. Epub 2010 May 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验